{"id":535254,"date":"2010-04-20T09:07:31","date_gmt":"2010-04-20T13:07:31","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=74627"},"modified":"2010-04-20T09:07:31","modified_gmt":"2010-04-20T13:07:31","slug":"ligand-pockets-6-5m-from-roche","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/535254","title":{"rendered":"Ligand Pockets $6.5M From Roche"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/Hepatitis-C\/\">Hepatitis C<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>San Diego-based Ligand Pharmaceuticals (NASDAQ: <a href=\"http:\/\/finance.yahoo.com\/q?s=LGND\">LGND<\/a>) <a href=\"http:\/\/investors.ligand.com\/releasedetail.cfm?ReleaseID=461314\">said today<\/a> it has earned a $6.5 million milestone payment from Switzerland-based Roche in connection with the advancement of a hepatitis C drug candidate into clinical trials. The product, RG7348, was the subject of a collaboration in 2008 between Roche and Metabasis Therapeutics, which Ligand acquired in January. Ligand will keep $2.3 million of the new milestone, pay about $2.7 million to former Metabasis shareholders who were issued a &#8220;contingent value right&#8221; to milestones from Roche, and use the rest to cover pre-existing contractual obligations.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/04\/20\/ligand-pockets-6-5m-from-roche\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Ligand%20Pockets%20$6.5M%20From%20Roche%20http:\/\/xconomy.com\/?p=74627\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/san-diego\/2010\/04\/20\/ligand-pockets-6-5m-from-roche\/&#038;t=Ligand%20Pockets%20$6.5M%20From%20Roche\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/san-diego\/2010\/04\/20\/ligand-pockets-6-5m-from-roche\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Ligand+Pockets+%246.5M+From+Roche&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fsan-diego%2F2010%2F04%2F20%2Fligand-pockets-6-5m-from-roche%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=b158a0e0f8d3e0e9af311916effca3c8&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=b158a0e0f8d3e0e9af311916effca3c8&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/ib.adnxs.com\/seg?add=24595&#038;t=2\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/qTHUBOUA5k0XQau_W_pzILsr8Yc\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/qTHUBOUA5k0XQau_W_pzILsr8Yc\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/qTHUBOUA5k0XQau_W_pzILsr8Yc\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/qTHUBOUA5k0XQau_W_pzILsr8Yc\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/RwYtelLPOgY\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, Hepatitis C, deals Luke Timmerman wrote: San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND) said today it has earned a $6.5 million milestone payment from Switzerland-based Roche in connection with the advancement of a hepatitis C drug candidate into clinical trials. The product, RG7348, was the subject of a collaboration in 2008 between Roche and Metabasis [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-535254","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/535254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=535254"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/535254\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=535254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=535254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=535254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}